Anti-MSLN antibody and pharmaceutical composition for cancer treatment comprising same
US11401343B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 22, 2018 |
| Grant date | Aug 2, 2022 |
| Priority date | — |
| Expiry date | Mar 2, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.